Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03975296
Other study ID # CXL3
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 10, 2019
Est. completion date January 11, 2021

Study information

Verified date March 2020
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is a prospective, randomized, single-center, open-label, parallel-arm, blinded-analysis trial, the objective of which is to evaluate the effect of transmuscular quadratus lumborum block (TMQLB) in the pain relief and quality of recovery in laparoscopic partial nephrectomy compared with thoracic paravertebral block (TPVB).


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 11, 2021
Est. primary completion date January 1, 2021
Accepts healthy volunteers No
Gender All
Age group 17 Years to 80 Years
Eligibility Inclusion Criteria: Age 18-70 yrs American Society of Anesthesiologists physical status?-? Undergo laparoscopic nephrectomy Informed consent Exclusion Criteria: A known allergy to the drugs being used Coagulopathy, on anticoagulants Analgesics intake, history of substance abuse Participating in the investigation of another experimental agent Inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
preoperative single-shot TMQLB
The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane. Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
preoperative single-shot TPVB
The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
Drug:
patient controlled intravenous analgesia(PCIA)
at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Cui Xulei

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary cumulative morphine consumption within 48 postoperative hours
Secondary The pain scores determined by the numeric rating scale (NRS, 0-10) NRS is an internationally recognized pain scale with 11 points ranging from 0 to 10 points, with 0 defined as no pain and 10 defined as the worst pain imaginable. within 48 postoperative hours
Secondary dermatomal distribution of sensory reduction Thirty minutes after the block, the bilateral dermatomal sensory blocks for the anterior abdomen (between the anterior axillary and mid-clavicular lines) and thigh were assessed with the pinprick method. A reduce in pinprick sensation relative to the unblocked side was interpreted as an effective block. 30 min after the block
Secondary quality of recovery evaluated by the self-assessment 15-item quality of recovery (QoR) scale QoR is a 15-item questionnaire which will score on a scale of 0-10 pertaining to patient's comfort, support system, pain, well-being, and ability to carry out daily activities, where 0 indicates none of the time and 10 indicates all of the time at 3 days and 5 days after the sugery
Secondary postoperative length of hospital stay time to patient's discharge within 2 weeks after the surgery
Secondary patient satisfaction with anesthesia use the Chinese version Bauer questionnaire to assess the patient satisfaction with anesthesia 48 hours after surgery
Secondary nausea and vomiting episodes within 24 hours after the surgery]
Secondary ambulation time time from the end of the surgery to the first time to out-of-bed activity within the 5 days after surgery
Secondary time of recovery of bowl movement within the 5 days after surgery
See also
  Status Clinical Trial Phase
Terminated NCT03414281 - TMQLB Versus TPVB for Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery N/A